home / stock / gern / gern articles

GERN Articles, Geron Corporation - From 03/12/24

Stock Information
Company Name: Geron Corporation
Stock Symbol: GERN
Market: NASDAQ
Website: geron.com
Menu
GERN GERN Quote GERN Short GERN News GERN Articles GERN Message Board
Get GERN Alerts

News, Short Squeeze, Breakout and More Instantly...
FDA Casts Doubts On Geron's Blood Cancer Drug, But Analyst Sees High Probability For Imetelstat's Potential Approval For MDS Anemia Treatment | Benzinga

The FDA’s Oncologic Drugs Advisory Committee will meet virtually on March 14, 2024, to review Geron Corporation’s (...
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session | Benzinga

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. Asana reported quarterly losse...

Director at Geron Acquires Company Stock Options Worth 200,000 Shares | Benzinga

Guarav Aggarwal, Director at Geron (NASDAQ:GERN), reported a large acquisition of company stock options on November 28, according to a new SEC fili...

Geron Chairman Awarded $1.07M Worth of Stock Options | Benzinga

John A Scarlett, Chairman at Geron (NASDAQ:GERN), reported a large acquisition of company stock options on September 22, according to a new SEC fil...
EVP at Geron Acquires Company Stock Options Worth 200,000 Shares | Benzinga

Faye Feller, EVP at Geron (NASDAQ:GERN), reported a large acquisition of company stock options on September 22, according to a new SEC filing. What...

EVP at Geron Acquires Company Stock Options Worth 221,544 Shares | Benzinga

Andrew J Grethlein, EVP at Geron (NASDAQ:GERN), reported a large acquisition of company stock options on September 22, according to a new SEC filin...

EVP at Geron Acquires Company Stock Options Worth 250,000 Shares | Benzinga

Olivia K. Bloom, EVP at Geron (NASDAQ:GERN), reported a large acquisition of company stock options on September 22, according to a new SEC filing. ...
Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs | Benzinga

Goldman Sachs has upgraded Geron Corporation (NASDAQ: GERN) to Buy from Neutral, with a price target of $4. Recently, the FDA a...

Previous 10 Next 10